• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 7th February 2019

OHE Response to Public Consultation on NICE Principles

OHE has submitted a response to the public consultation on updating the principles that guide the development of NICE guidance and standards. The National Institute for Health and Care Excellence (NICE) has been running a public consultation on updating the…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

OHE has submitted a response to the public consultation on updating the principles that guide the development of NICE guidance and standards.

The National Institute for Health and Care Excellence (NICE) has been running a public consultation on updating the principles that guide the development of its guidance and standards. Underpinning the consultation is a draft document [PDF] setting out NICE’s key principles, bringing together existing statements about the Institute’s current practices. The final document is intended to replace NICE’s current guide to its Social Value Judgements [PDF]. The consultation runs until 11th February 2019, and OHE recently submitted a response.

OHE’s response focused on principles 5 and 6 of the draft document. Principle 5 describes how organisations representing patients, service users, carers and the wider public are involved in defining the scope of NICE products and are invited to submit evidence for its advisory committees to consider. This seems reasonably clear for input into specific guidance (e.g. the appraisal of a specific technology) but it is less clear whether and how these groups will have the opportunity to provide input into more general guidance and value judgements adopted by NICE and its advisory committees.

The Social Value Judgements guide states the following: “The NHS is funded from general taxation, and it is right that UK citizens have the opportunity to be involved in the decisions about how the NHS’s limited resources should be allocated” (p.10). It is unclear whether this statement still holds, and it appears that NICE’s Citizens Council has not been active in recent years. It would be helpful to see a commitment from NICE to consider research (e.g. from academic groups) that generates and analyses evidence on the views of different groups (e.g. public, patients) on issues related to social value. We believe that public sector resource allocation decisions should be informed by information on societal preferences.

More generally, while the new principles document is intended to replace the Social Value Judgements guide, we note that the content of the two documents differs considerably. The Social Value Judgements guide contains useful information on how NICE considers factors such as individual choice, rare conditions, rule of rescue, avoiding discrimination, equality and inequalities. In our consultation response, we suggested that NICE could provide information on whether there is anything from the soon-to-be-defunct guide that has not been absorbed into the various methods and process manuals.

Principle 6 notes that where specific criteria are satisfied, life-extending end of life treatments and highly specialised technologies may be recommended with cost-effectiveness estimates above the normally acceptable range. We have suggested that it would be helpful to provide a brief explanation of the rationale(s) for this. It is also unclear whether these are the only exceptions to the standard value for money assessment approach. For example, we note that the factors influencing judgements about the acceptability of a technology listed in section 6.3.3 of NICE’s Guide to Methods of Technology Appraisal (e.g. innovative nature of the technology, aspects that related to non-health objectives of the NHS) are not mentioned in the draft principles document. In addition, estimates of opportunity cost may be different for public health and social care interventions (compared to health care interventions), hence a different threshold, or alternative decision criteria, may be relevant. NICE’s position on this is unclear.

Finally, we note that NICE uses an opportunity cost threshold, while various Government departments use alternative approaches to assess value for money, such as a threshold or value of a statistical life based on willingness-to-pay data. Some explanation of the reason(s) for this difference would be useful.

OHE has undertaken research and written extensively about some of the issues raised in this consultation. Examples include:

  • A journal article reviewing the methods used in NICE’s various health technology assessment programmes (subject of a previous blog post)
  • A programme of research examining NICE’s policy for the appraisal of life-extending end of life treatments and the extent of public support for the policy (subject of several previous blog posts, including here)
  • A consulting report examining the way in which treatments for very rare diseases are appraised (subject of a previous blog post)
  • A journal article describing NICE’s social value judgements about equity in health and health care
  • A blog post highlighting the application of NICE principles and social value judgements in a recent technology appraisal
  • A programme of work seeking to better understand the opportunity costs of new health care technologies, highlighted in a previous blog post and a consulting report
  • Ongoing research to explore the trade-offs being made in the allocation of taxation budgets across the public sector

For more information, please contact Koonal Shah.

Related research

Cowles, E., Marsden, G., Cole, A. and Devlin, N., 2017. A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact? Applied Health Economics and Health Policy, 15(4), pp.469-477. DOI. RePEc.

Shah, K.K., Cookson, R., Culyer, A. and Littlejohns, P., 2013. NICE’s Social Value Judgements about Equity In Health And Health Care. Health Economics, Policy and Law, 8(2), pp.145-165. DOI. RePEc.

Shah, K.K., 2017. Valuing Health at the End of Life. PhD thesis. Sheffield: University of Sheffield.

Towse, A. and Garau, M., 2018. Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence. Consulting Report. London: Office of Health Economics. RePEc.

  • Health Technology Assessment…
  • Value, Affordability, and…
  • NICE

Related News

  • News
  • November 2021

Opportunity Cost in Health Care: a Favourite Research Topic for OHE

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
  • News
  • August 2020

Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?

Read more
  • News
  • July 2020

NICE ‘Optimised’ Recommendations: What Do They Mean for Patient Access?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!